Mirum Pharmaceuticals, Inc. (MIRM) stock
MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$91.95+0.37 (+0.40%)
Close on Nov 17, 2026Market cap $5.97BP/E –Yield –
Mirum Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Mirum Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $282.51M, up 73.5% year over year. For fiscal 2025 it was $186.18M, up 32.4% from the year before. The highest annual figure on record is $186.18M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.18M | +32.4% |
| FY2024 | Dec 31, 2024 | $140.63M | +37.1% |
| FY2023 | Dec 31, 2023 | $102.61M | -4.0% |
| FY2022 | Dec 31, 2022 | $106.84M | -18.7% |
| FY2021 | Dec 31, 2021 | $131.43M | +61.1% |
| FY2020 | Dec 31, 2020 | $81.61M | +89.8% |
| FY2019 | Dec 31, 2019 | $42.99M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $90.53M | +96.5% |
| Q1 FY2026 | Mar 31, 2026 | $97.91M | +138.5% |
| Q4 FY2025 | Dec 31, 2025 | $51.11M | +16.1% |
| Q3 FY2025 | Sep 30, 2025 | $42.96M | +35.5% |
| Q2 FY2025 | Jun 30, 2025 | $46.07M | +41.0% |
| Q1 FY2025 | Mar 31, 2025 | $41.04M | +27.4% |
| Q4 FY2024 | Dec 31, 2024 | $44.03M | +42.3% |
| Q3 FY2024 | Sep 30, 2024 | $31.71M | +21.4% |
| Q2 FY2024 | Jun 30, 2024 | $32.67M | +5.0% |
| Q1 FY2024 | Mar 31, 2024 | $32.22M | +22.9% |
| Q4 FY2023 | Dec 31, 2023 | $30.94M | +21.6% |
| Q3 FY2023 | Sep 30, 2023 | $26.12M | +8.4% |
| Q4 FY2022 | Dec 31, 2022 | $31.11M | +12.0% |
| Q3 FY2022 | Sep 30, 2022 | $26.22M | -14.0% |
| Q2 FY2022 | Jun 30, 2022 | $25.43M | -27.4% |
| Q1 FY2022 | Mar 31, 2022 | $24.09M | -36.8% |
| Q4 FY2021 | Dec 31, 2021 | $27.78M | -6.6% |
| Q3 FY2021 | Sep 30, 2021 | $30.47M | +90.6% |
| Q2 FY2021 | Jun 30, 2021 | $35.05M | +88.9% |
| Q1 FY2021 | Mar 31, 2021 | $38.13M | +119.9% |
| Q4 FY2020 | Dec 31, 2020 | $29.73M | +106.7% |
| Q3 FY2020 | Sep 30, 2020 | $15.98M | +31.5% |
| Q2 FY2020 | Jun 30, 2020 | $18.56M | +60.1% |
| Q1 FY2020 | Mar 31, 2020 | $17.34M | +256.6% |
| Q4 FY2019 | Dec 31, 2019 | $14.38M | +479233.3% |
| Q3 FY2019 | Sep 30, 2019 | $12.16M | – |
| Q2 FY2019 | Jun 30, 2019 | $11.59M | – |
| Q1 FY2019 | Mar 31, 2019 | $4.86M | – |
| Q3 FY2018 | Sep 30, 2018 | $3.00K | – |
See a number that looks wrong?